SCHEMBL5127697

SCHEMBL5127697

C#Cc1ccsc1-c1nc2cc(C)ccn2c1NCc1ccccc1OC.c1cc2cc-2c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.44
GAA P10253 6/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 2/20 0.44
KDM4E B2RXH2 1/20 0.44
POLB P06746 1/20 0.44
PKM P14618 1/20 0.42
PKLR P30613 1/20 0.42
ATM Q13315 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
MAPK1 P28482 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
NR1H4 Q96RI1 3/20 0.39
THRB P10828 1/20 0.37
TP53 P04637 2/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122321 0.92 KDM4E (0.40) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5128392 0.91 NR1H4 (0.47) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5122359 0.88 TP53 (0.38) MAPTGAASMN1; SMN2ALDH1A1KDM4E
SCHEMBL5130393 0.86 GAA (0.51) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5127031 0.84 ALDH1A1 (0.50) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5128014 0.81 NR1H4 (0.49) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5113157 0.80 NR1H4 (0.42) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5129077 0.79 ATM (0.43) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5127659 0.78 KDM4E (0.51) MAPTGAASMN1; SMN2RAB9AALDH1A1
SCHEMBL5129230 0.78 NR1H4 (0.44) MAPTGAASMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS MAPT 707/4885GAA 234/4885SMN1; SMN2 1463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.